Insulin device maker Insulet Corporation (NASDAQ: PODD ) reported a second-quarter adjusted EPS of $0.55 on Thursday, missing the consensus estimate of $0.56 . It reported an EPS of $0.38 a year ago. The company reported sales of $488.5 million, beating the consensus of $463.31 million, which is in line with the preliminary earnings reported in July . The sales increased 23.2% year over year, or 23.4% in constant currency, exceeding the company’s guidance of 18% due to revenue outperformance for all product lines . Omnipod revenue of $480.4 million, an increase of 26.3% (+26.5% in constant currency) U.S. Omnipod revenue of $352.3 million, an increase of 27.3% International Omnipod revenue of $128.1 million, an increase of 23.5%, or 24.4% in constant currency “We remain the clear leader in our industry, and in light of our first half … Full story available on Benzinga.com

These are the stocks posting the largest moves in premarket trading.

The following slide deck was published by Insulet Corporation in conjunction with their 2024 Q2 earnings call.

Raising Full Year Revenue, Gross Margin and Operating Margin Guidance ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for the three months ended June 30, 2024. Second Quarter Financial Highlights: Second quarter 2024 revenue of […] The post Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year appeared first on Fintech News .

Insulet (NASDAQ: PODD ) just reported results for the second quarter of 2024. Insulet reported earnings per share of 55 cents. This was below the analyst estimate for EPS of 56 cents. The company reported revenue of $488.50 million. This was 6.21% better than the analyst estimate for revenue of $459.93 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace Legendary Investor Predicts: “Forget AI… THIS Technology Is the Future” The post PODD Stock Earnings: Insulet Misses EPS, Beats Revenue for Q2 2024 appeared first on InvestorPlace .

Insulet Corporation (NASDAQ:NASDAQ:PODD) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ETCompany ParticipantsDeborah Gordon - Vice President,…

WASHINGTON (dpa-AFX) - Insulet Corp. (PODD) announced earnings for its second quarter that increased from the same period last year but missed the Street estimates.The company''s earnings totaled $…

Insulet (NASDAQ: PODD ) has outperformed the market over the past 10 years by 8.61% on an annualized basis producing an average annual return of 19.14%. Currently, Insulet has a market capitalization of $13.31 billion. Buying $100 In PODD: If an … Full story available on Benzinga.com

WASHINGTON (dpa-AFX) - Insulet Corp. (PODD), a tubeless insulin pump technology with its Omnipod brand of products, on Friday registered a rise in preliminary revenue for the second-quarter to $48…

Insulet Corporation (NASDAQ: PODD ) shares are trading higher after the company reported preliminary second-quarter results. The company reported preliminary revenue of $488 million for the second quarter of 2024, marking a 23% increase from the $397 million reported in the previous year. The figure outpaces the street view of $460.27 million. “Second quarter revenue exceeded our expectations across the board as a result of strong demand for Omnipod 5, resulting in robust revenue … Full story available on Benzinga.com